Now people are gaining awareness about financial planning and goal planning as many intermediaries like insurance agents, mutual fund distributors are educating investors about their importance. So let’s find out how we can do goal planning with mutual funds.

Sun Pharma Advanced Research Company (SPARC) announced a research collaboration with Schrodinger by means of which the two entities aim to accelerate the Neurodegeneration Drug Development Program.

India’s top pharma company, Sun Pharma received final approval from the USFDA for its Abbreviated New Drug Application (ANDA) for the generic version of Generic Ganirelix Acetate injection, 250 mcg/0.5 ml.

The stock of Reliance Telecommunication (Rcom) spiked up in the early morning session on Monday, reacting to the Supreme Court order that allows the company to go ahead with the spectrum sale after ensuring a corporate guarantee from Reliance Realty.

Overall volumes in futures & options currently stand at 74.64 lakhs contracts with a turnover of Rs. 4,39,239.97 crore.

Overall volumes in futures & options currently stand at 74.64 lakhs contracts with a turnover of Rs. 4,39,239.97 crore.

In the coming session, Nifty has an immediate resistance around the level of 10,920 and a follow-through move above this level may take Nifty towards its 100-day moving average, i.e. 10,958. Stocks in news: Sun Pharma Advanced Research (SPARC), Biocon, Laurus Labs, Monte Carlo Fashions, BHEL, Genus Paper and Boards, Ashiana Housing, M&M Fin, VIP Clothing and Cadila Healthcare.

Indian benchmark indices are likely to open with a gap-up largely in tandem with the firm trend in other Asian bourses as investors cheered the news that Donald Trump and Xi Jinping have agreed to a temporary truce on the trade war. On Friday, the GDP data released after market hours  indicated that the Indian economy growth slowed to 7.1 per cent in the September quarter. Auto stocks will be in focus today as companies released monthly sales figures over the weekend.  The SGX Nifty Index Future was trading higher by 73 points at 10,983.

Zydus Cadila has received the final approval for Teriflunomide tablets from the United States of Food and Drug Association (USFDA). Shares of the company could most likely be in limelight on Monday’s trading session.

IDBI bounced almost 30 per cent from its previous support zone and then it has been trading in a narrow contracting trading range since early October. This stock recently occurred in our Bollinger Band Squeeze scanner which suggests that consolidation breakout is near.